Not Signed In - Acuity Pharmaceuticals Reports Positive Phase II Results For Bevasiranib In Wet AMD
Tue, 12 Sep 2006 07:00 AM EST
... Acuity Pharmaceuticals, a clinical stage ophthalmic pharmaceutical company, todayannounced positive results from its Phase II C.A.R.E(TM) trial forbevasiranib sodium (formerly Cand5), Acuity's lead compound for thetreatment of wet age-related macular degeneration (wet AMD). [click link for full article] ...
Related Topics
- Age-Related Macular Degeneration
- Wet Lung
- Clinical Trials
- Nystatin and Triamcinolone
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Tb
- Macular Degeneration
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Well Baby Reports
- Tuberculosis Surveillance Reports
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
- Sexually Transmitted Disease Surveillance Reports
- Vaccine Safety and Adverse Event Reports
- Kniest dysplasia
- HLA-B27
- Triple Screen
- Juvenile Diabetes
- Membranoproliferative GN II
email this page
print this page
bookmark this page
feedback on this page
